Precision Medicine in Phase I Cancer Trials

In this video we discuss the use of biomarker-guided treatment in phase I trials, which can yield high response rates.

A meta-analysis of 351 phase I clinical trials found that using precision medicine techniques including biomarker-guided treatment, especially with targeted therapies, can yield high response rates, according to data presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held earlier this month in Chicago (abstract 11520).

Here Maria Schwaederle, PharmD, of the UC San Diego Moores Cancer Center in La Jolla, California, discusses results of the trial.